The economic impact of startups connected with the UNC Eshelman School of Pharmacy and the University of North Carolina at Chapel Hill continues to grow across the Tar Heel State. A recent semi-annual analysis conducted by Innovate Carolina, UNC-Chapel Hill’s innovation … Continued
University of North Carolina Eshelman School of Pharmacy has developed a panel of ultrapotent sperm-binding monoclonal antibodies as option for affordable, non-hormonal female contraception Scientists at the University of North Carolina at Chapel Hill are engineering molecularly tuned monoclonal antibodies … Continued
Sam Lai Ph.D., has been promoted to full professor in the Division of Pharmacoengineering and Molecular Pharmaceutics at the UNC Eshelman School of Pharmacy, effective March 25. “I am grateful for this promotion, and it is a reflection of … Continued
The North Carolina Policy Collaboratory based at UNC-Chapel Hill will distribute $29 million toward 85 research projects focused on treatment, community testing and prevention of COVID-19. The rollout includes four projects from the UNC Eshelman School of Pharmacy. Each of … Continued
Sam Lai, Ph.D., an associate professor at the UNC Eshelman School of Pharmacy’s Division of Pharmacoengineering and Molecular Pharmaceutics, has received two separate R01 awards from the National Institutes of Health totaling $3.5M to develop antibodies for non-hormonal contraception. The … Continued
The NC TraCS Institute announced pilot grant awards to researchers focused on COVID-19. In total, 34 applications were received and eight were chosen for funding. Awardees include investigators from UNC’s Eshelman School of Pharmacy, Gillings School of Global Public Health, … Continued
An interdisciplinary team from the University of North Carolina at Chapel Hill has received funding to explore the critical role of airway mucus in the transmission, infection and spread versus protection from COVID-19. While the world waits for a vaccine … Continued
The Eshelman Institute for Innovation (EII) recently awarded Sam Lai, Ph.D., a $50,000 opportunistic grant to pursue COVID-19 research. The award will fund the development of a number of nebulized monoclonal antibody (mAb)-based therapy against COVID-19. This is based on … Continued
The E(I) Lab didn’t let COVID-19 keep them from hosting their 5th annual awards ceremony for solving challenges in healthcare. Participants gathered virtually, which allowed the four teams who have been working over the past six months to still present … Continued
Mucommune LLC has been awarded over $3 million in five separate federal grants over the past several months to advance its muco-trapping antibody technology. The company was launched in 2016 by Sam Lai, Ph.D., an associate professor at the UNC … Continued
